Latest news
Business Update
Innosuisse-Funded Alzheimer’s Clinical Trial with MIAMIND®
The MIAMIND® electrical neurostimulator will be evaluated in a randomized, sham-controlled clinical trial in patients with early-stage Alzheimer’s disease (AD), supported by funding from Innosuisse.
08 April, 2026
Read more
Business Update | Wed 11, 2024
Dr. Filip Barinka joins Priority Access Program
We are thrilled to announce that Dr. Filip Barinka at the Altersneurologie Gedächtnis-Sprechstunde, in collaboration with the Swiss Neuro Radiology In
Business Update | Wed 11, 2024
Bellevue Medical Group joins Priority Access Program
We are excited to introduce the Bellevue Medical Group (BMG) as an early adopter of our Priority Access Program for Alzheimer’s patients!
Featured | Tue 11, 2024
Tagesanzeiger Article
We’re proud to announce that our article has been featured in the latest edition of Tages-Anzeiger.
Business Update | Thu 10, 2024
TOP Swiss Medtech Startups 2024
Proud to announce that Bottneuro was selected as one of 15 of the most promising Swiss MedTech Startups and Scale-Ups of 2024.
Featured news
Bottneuro Team
Dr Antonella Santuccione Chadha joins the Board of Directors at Bottneuro
02 June, 2025
